A new acridine derivative induces cell cycle arrest and antiangiogenic effect on Ehrlich ascites carcinoma model
作者:Vivianne Mendes Mangueira、Tatianne Mota Batista、Monalisa Taveira Brito、Tatyanna Kelvia Gomes de Sousa、Ryldene Marques Duarte da Cruz、Renata Albuquerque de Abrantes、Robson Cavalcanti Veras、Isac Almeida de Medeiros、Karina Karla de Paula Medeiros、Ana Ligia da Costa Pereira、Vanessa de Lima Serafim、Ricardo Olímpio de Moura、Marianna Vieira Sobral
DOI:10.1016/j.biopha.2017.03.049
日期:2017.6
ACS-AZ10 (15 or 30mg/kg) displayed significant antitumor activity considering the tumor weight and volume, cell viability, and total Ehrlich cell count. ACS-AZ10 (7.5mg/kg) induced an increase in sub-G1 peak, suggesting apoptosis. At 15mg/kg ACS-AZ10 induced cell cycle arrest in G2/M phase and a reduction in the percentage of cells in G0/G1 and S phases, suggesting a pre-mitotic blockade. ACS-AZ10 reduced
背景技术A啶衍生物,包括amsacrine,具有抗肿瘤活性。但是,副作用,耐药性的发展及其低生物利用度限制了它们的使用。在这里,我们描述了合成过程,并评估了一种新的氨酚精类似物N'-(2-氯-6-甲氧基-ac啶-9-基)-2-氰基-3-(4-二甲基氨基苯基)的毒性和抗肿瘤活性)-acrilohidrazida(ACS-AZ10)。方法该化合物是通过线性途径获得的,在该途径中,ASC-Az中间体是通过将6,9-二氯-3-甲氧基-啶和2-ciany-acethihidrazide偶联,然后与相应的醛缩合而获得的。使用急性毒性和微核试验评估了ACS-AZ10在小鼠中的毒性。使用艾氏腹水癌模型研究ACS-AZ10(7.5、15或30mg / kg,腹膜内注射)的抗肿瘤活性和毒性 ),经过9天的治疗。还评估了细胞周期和血管生成。结果获得的ASC-AZ10具有令人满意的产率,并且通过光谱和光谱技术证实